Gaeta Therapeutics

Gaeta Therapeutics was founded by the University of Zurich in 2017 as a vehicle for the commercialization of its immunotherapy patents, involving the combination of interleukin-12 (IL-12) with checkpoint inhibitors for cancer treatment.